» Articles » PMID: 8634828

Inhibition of Rat Liver Mitochondrial Monoamine Oxidase by Hydrazine-thiazole Derivatives: Structure-activity Relationships

Overview
Journal Bioorg Med Chem
Specialties Biochemistry
Chemistry
Date 1995 Nov 1
PMID 8634828
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The purpose of this research is to study the relationship between chemical structure and inhibitory activity of some hydrazine-thiazole derivatives on rat liver mitochondria monoamine oxidase (MAO). Forty-five compounds belonging to three series of hydrazine-thiazole derivatives, with either alkylic or arylic substituents in the thiazole ring, were tested. The highest inhibitory activity was observed with piperonyl derivatives 25 and 40, which contain a 4-methyl group in the thiazole nucleus. The structure-activity relationship of MAO inhibitors was established in relation to hydrophobic, electronic and steric hindrance parameters. A mechanism of enzyme inhibition was proposed based on the calculation of HOMO energies.

Citing Articles

Design, Synthesis, and Biological Effect Studies of Novel Benzofuran-Thiazolylhydrazone Derivatives as Monoamine Oxidase Inhibitors.

Osmani Ye D, Saglik B, Levent S, Cevi K U, Ilgin S, Yurttas L ACS Omega. 2024; 9(10):11388-11397.

PMID: 38496951 PMC: 10938434. DOI: 10.1021/acsomega.3c07703.


Remodelin Is a Cryptic Assay Interference Chemotype That Does Not Inhibit NAT10-Dependent Cytidine Acetylation.

Shrimp J, Jing Y, Thalalla Gamage S, Nelson K, Han J, Bryson K ACS Med Chem Lett. 2021; 12(6):887-892.

PMID: 34141066 PMC: 8201477. DOI: 10.1021/acsmedchemlett.0c00193.


Design, Synthesis, In Vitro and In Silico Studies of New Thiazolylhydrazine-Piperazine Derivatives as Selective MAO-A Inhibitors.

Saglik B, Cebeci O, Acar Cevik U, Osmaniye D, Levent S, Kaya Cavusoglu B Molecules. 2020; 25(18).

PMID: 32971892 PMC: 7571065. DOI: 10.3390/molecules25184342.


Tau as a therapeutic target in neurodegenerative disease.

Himmelstein D, Ward S, Lancia J, Patterson K, Binder L Pharmacol Ther. 2012; 136(1):8-22.

PMID: 22790092 PMC: 3697479. DOI: 10.1016/j.pharmthera.2012.07.001.